Tackling these resistance mechanisms may require combination approaches, such as pairing PARP inhibitors with ATR or WEE1 inhibitors to prevent replication stress recovery, or with checkpoint inhibitors to enhance tumor immunogenicity (57, 58). Here, WEE1 is linked to neoplasm.